Synthetic biology company Pearl Bio has signed a licence, partnership and option agreement with Merck for the discovery of biologic therapies that incorporate non-standard amino acids to treat cancer.
The partnership is underpinned by the substantial expertise and patents from its scientific co-founders’ laboratories which focus on the use of genomically recoded organisms (GROs) for encoding synthetic chemistries.
This approach is expected to create new classes of multi-functionalised biologics with adjustable properties.
The alliance will leverage Pearl’s GRO technology, along with its expertise in both cell-based and cell-free systems and the use of tethered ribosomes for encoding synthetic monomers. to target epitopes that were previously inaccessible.
Pearl is entitled to receive $1bn in combined upfront, option and milestone payments from Merck.
The company will receive royalty payments on the sales of any approved products that emerge from the partnership.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Merck Research Laboratories Discovery Biologics vice-president Juan Alvarez stated: “Merck is excited to collaborate with Pearl, a pioneer in developing recoded organisms, to produce novel biologics enabled by synthetic chemistries.”
Pearl Bio, supported by Khosla Ventures, focuses on advancing its platform technology to develop multi-functionalised biologics and biomaterials through encoding synthetic chemistries.
The company is expanding its capabilities both in-house and via strategic pharmaceutical collaborations.
Pearl Bio co-founder and president Amy Cayne Schwartz stated: “We are excited to demonstrate the power of Pearl’s technology in our partnership with Merck to create multi-functionalised therapeutic candidates with tunable properties solving for some of the key shortcomings confronting biologics.”
The latest development comes after Merck concluded the acquisition of Harpoon Therapeutics for $680m in early 2024, broadening its oncology pipeline.
Source link
#Pearl #Bio #Merck #partner #discovery #cancer #therapies
